Trial Profile
A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Taladegib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2023 Status changed from completed to discontinued.
- 16 Feb 2022 Status changed from active, no longer recruiting to completed.
- 20 Nov 2020 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.